Special Issue "The Role of Src Kinase Family in Cancer"
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (15 May 2020).
Interests: cancer; tyrosine kinases; serine-threonine kinases; kinase inhibitors; small molecules; organic synthesis; ADME studies; drug formulations
Special Issues and Collections in MDPI journals
The involvement of many tyrosine kinases in cancers has been strongly demonstrated. These enzymes include receptor or transmembrane kinases and cytoplasmic or non-receptor kinases. Src family kinases (SFKs) are the biggest class of non-receptor tyrosine kinases, and consist of nine highly homologous members.
SFKs regulate multiple signal transduction pathways which are involved in cell growth, proliferation, differentiation, migration, and apoptosis, in addition to playing important roles in angiogenesis. All these functions are altered in cancer. It has been widely demonstrated that while SFK activities are strictly regulated in healthy cells, some SFK members are overexpressed and/or hyperactivated in many solid and hematological cancers and are promoting factors for the development of metastatic cancer phenotypes.
Many biological roles have been demonstrated for SFKs. Src, which was the first SFK identified and is the most-studied enzyme belonging to this family, provides a well-known case-in-point.
The Src inhibitors dasatinib, bosutinib, and ponatinib, which also target other similar kinases, have been approved for chronic myeloid leukemia treatment, while other compounds, including saracatinib, are in clinical trials for their potential applications in many tumors. Other SFK inhibitors are being developed and are in preclinical studies.
This Special Issue is devoted to investigations that highlight further roles played by SFKs in cancer development, and studies that will lead to new potentially useful SFK inhibitors that could improve specific anticancer therapies.
Prof. Dr. Silvia Schenone
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Src family kinases
- cell pathways
- cancer therapy
- kinase inhibitors